Epi Biotech Co Ltd

Epi Biotech's capital structure is highly leveraged, with total liabilities of KRW 17.2 billion and total equity of -KRW 11.9 billion, resulting in a negative debt-to-equity ratio of -0.84. The company's liquidity position is weak, with a current ratio of 0.18 and only KRW 708.5 million in cash and equivalents, which is insufficient to cover its total liabilities. The company's free cash flow is negative at -KRW 1.49 billion, indicating ongoing cash outflows from operations after capital expenditures. Profitability metrics show significant underperformance. The company reported a net loss of KRW 1.91 billion and an operating loss of KRW 2.08 billion, with a return on assets of -36.05%. While the return on equity is positive at 16.04%, this is largely due to the negative equity base, which inflates the ratio. These figures are well below the industry median for profitability and returns. The company's revenue is concentrated in its core biopharmaceutical and CDMO services, with no disclosed geographic diversification. Given the lack of segmental or geographic breakdown in the financial data, it is unclear whether the company has significant exposure to any particular region or market. Growth trajectory is uncertain. The company is currently reporting declining operating and net income, with no clear indication of future revenue growth. The negative operating cash flow of -KRW 662.9 million and free cash flow of -KRW 1.49 billion suggest ongoing operational challenges. Risk factors include high leverage and negative equity, which increase the company's vulnerability to financial distress. The risk assessment indicates a medium liquidity risk and a low dilution risk, but the company's negative net cash position after subtracting total debt is a key flag. The company has not disclosed any recent dilutive events, and the dilution potential is currently low. Recent events include the latest financial filing, which shows continued losses and negative cash flows. No recent earnings call transcripts or other material events have been disclosed in the provided data.